Drug Profile
Leriglitazone - Minoryx Therapeutics
Alternative Names: Leriglitazone hydrochloride; MIN-102Latest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator IDIBELL
- Developer Minoryx Therapeutics
- Class Neuroprotectants; Phenyl ethers; Pyridines; Small molecules; Thiazolidinediones
- Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Adrenoleucodystrophy
- Phase II Friedreich's ataxia
- Preclinical CNS disorders
Most Recent Events
- 02 Feb 2024 Minoryx and Neuraxpharm seeking a re-examination for conditional approval for patients with cerebral adrenoleukodystrophy (cALD)
- 26 Jan 2024 EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended not to grant marketing authorization for leriglitazone as a treatment of X-ALD
- 12 Jul 2023 Phase-III clinical trials in Adrenoleucodystrophy in USA (PO) (NCT05819866)